MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 564079 | Name: PU-H71 hydrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PU-H71 hydrate is a potent inhibitor of heat shock protein 90 (Hsp90).

Chemical Structure

PU-H71 hydrate
PU-H71 hydrate
CAS#1202865-65-3 (H2O)

Theoretical Analysis

MedKoo Cat#: 564079

Name: PU-H71 hydrate

CAS#: 1202865-65-3 (H2O)

Chemical Formula: C18H23IN6O3S

Exact Mass: 0.0000

Molecular Weight: 530.39

Elemental Analysis: C, 40.76; H, 4.37; I, 23.93; N, 15.85; O, 9.05; S, 6.04

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
873436-91-0 (free base) 1202865-65-3 (H2O)
Synonym
PU H71 hydrate; PUH71 hydrate; PU-H71 hydrate
IUPAC/Chemical Name
6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine hydrate
InChi Key
ZUGBRIZOLBTCHT-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H21IN6O2S.H2O/c1-10(2)21-4-3-5-25-17-15(16(20)22-8-23-17)24-18(25)28-14-7-13-12(6-11(14)19)26-9-27-13;/h6-8,10,21H,3-5,9H2,1-2H3,(H2,20,22,23);1H2
SMILES Code
CC(NCCCN1C(SC2=C(I)C=C(OCO3)C3=C2)=NC4=C(N)N=CN=C14)C.[H]O[H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 530.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bay S, Digwal CS, Rodilla Martín AM, Sharma S, Stanisavljevic A, Rodina A, Attaran A, Roychowdhury T, Parikh K, Toth E, Panchal P, Rosiek E, Pasala C, Arancio O, Fraser PE, Alldred MJ, Prado MAM, Ginsberg SD, Chiosis G. Synthesis and Characterization of Click Chemical Probes for Single-Cell Resolution Detection of Epichaperomes in Neurodegenerative Disorders. Biomedicines. 2024 Jun 4;12(6):1252. doi: 10.3390/biomedicines12061252. PMID: 38927459; PMCID: PMC11201208. 2: Mohammed OA, Youssef ME, Doghish AS, Hamad RS, Abdel-Reheim MA, Alghamdi M, Alamri MMS, Alfaifi J, Adam MIE, Alharthi MH, Alhalafi AH, Bahashwan E, Rezigalla AA, BinAfif DF, Abdel-Ghany S, Attia MA, Elmorsy EA, Al-Noshokaty TM, Fikry H, Saleh LA, Saber S. A novel combination therapy targets sonic hedgehog signaling by the dual inhibition of HMG-CoA reductase and HSP90 in rats with non-alcoholic steatohepatitis. Eur J Pharm Sci. 2024 Jul 1;198:106792. doi: 10.1016/j.ejps.2024.106792. Epub 2024 May 5. PMID: 38714237. 3: Seipel K, Mandhair H, Bacher U, Pabst T. FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia. Curr Issues Mol Biol. 2024 Mar 29;46(4):2946-2960. doi: 10.3390/cimb46040184. PMID: 38666914; PMCID: PMC11049208. 4: Vogt M, Dienstbier N, Schliehe-Diecks J, Scharov K, Tu JW, Gebing P, Hogenkamp J, Bilen BS, Furlan S, Picard D, Remke M, Yasin L, Bickel D, Kalia M, Iacoangeli A, Lenz T, Stühler K, Pandyra AA, Hauer J, Fischer U, Wagener R, Borkhardt A, Bhatia S. Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells. Cell Death Dis. 2023 Dec 6;14(12):799. doi: 10.1038/s41419-023-06337-3. PMID: 38057328; PMCID: PMC10700369. 5: Seipel K, Kohler S, Bacher U, Pabst T. HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia. Curr Issues Mol Biol. 2023 Aug 23;45(9):7011-7026. doi: 10.3390/cimb45090443. PMID: 37754227; PMCID: PMC10529370. 6: Que NLS, Seidler PM, Aw WJ, Chiosis G, Gewirth DT. Selective inhibition of hsp90 paralogs: Structure and binding studies uncover the role of helix 1 in Grp94-selective ligand binding. bioRxiv [Preprint]. 2023 Aug 1:2023.07.31.551342. doi: 10.1101/2023.07.31.551342. PMID: 37577523; PMCID: PMC10418071. 7: Carter BZ, Mak PY, Muftuoglu M, Tao W, Ke B, Pei J, Bedoy AD, Ostermann LB, Nishida Y, Isgandarova S, Sobieski M, Nguyen N, Powell RT, Martinez-Moczygemba M, Stephan C, Basyal M, Pemmaraju N, Boettcher S, Ebert BL, Shpall EJ, Wallner B, Morgan RA, Karras GI, Moll UM, Andreeff M. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood. 2023 Sep 21;142(12):1056-1070. doi: 10.1182/blood.2022019047. PMID: 37339579; PMCID: PMC10656725. 8: Li P, Bai C, Zhan L, Zhang H, Zhang Y, Zhang W, Wang Y, Zhao J. Specific gene module pair-based target identification and drug discovery. Front Pharmacol. 2023 Jan 16;13:1089217. doi: 10.3389/fphar.2022.1089217. PMID: 36726786; PMCID: PMC9886283. 9: Cools R, Vermeulen K, Narykina V, Leitao RCF, Bormans G. Radiosynthesis and preclinical evaluation of [11C]SNX-ab as an Hsp90α,β isoform- selective PET probe for in vivo brain and tumour imaging. EJNMMI Radiopharm Chem. 2023 Jan 30;8(1):2. doi: 10.1186/s41181-023-00189-0. PMID: 36715827; PMCID: PMC9886718. 10: Rickner HD, Jiang L, Hong R, O'Neill NK, Mojica CA, Snyder BJ, Zhang L, Shaw D, Medalla M, Wolozin B, Cheng CS. Single cell transcriptomic profiling of a neuron-astrocyte assembloid tauopathy model. Nat Commun. 2022 Oct 21;13(1):6275. doi: 10.1038/s41467-022-34005-1. PMID: 36271092; PMCID: PMC9587045. 11: Sharma S, Kalidindi T, Joshi S, Digwal CS, Panchal P, Burnazi E, Lee SG, Pillarsetty N, Chiosis G. Synthesis of 124I-labeled epichaperome probes and assessment in visualizing pathologic protein-protein interaction networks in tumor bearing mice. STAR Protoc. 2022 Apr 19;3(2):101318. doi: 10.1016/j.xpro.2022.101318. PMID: 35496791; PMCID: PMC9046997. 12: Joshi S, Gomes ED, Wang T, Corben A, Taldone T, Gandu S, Xu C, Sharma S, Buddaseth S, Yan P, Chan LYL, Gokce A, Rajasekhar VK, Shrestha L, Panchal P, Almodovar J, Digwal CS, Rodina A, Merugu S, Pillarsetty N, Miclea V, Peter RI, Wang W, Ginsberg SD, Tang L, Mattar M, de Stanchina E, Yu KH, Lowery M, Grbovic- Huezo O, O'Reilly EM, Janjigian Y, Healey JH, Jarnagin WR, Allen PJ, Sander C, Erdjument-Bromage H, Neubert TA, Leach SD, Chiosis G. Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer. Commun Biol. 2021 Nov 25;4(1):1333. doi: 10.1038/s42003-021-02842-3. PMID: 34824367; PMCID: PMC8617294. 13: Ginsberg SD, Joshi S, Sharma S, Guzman G, Wang T, Arancio O, Chiosis G. The penalty of stress - Epichaperomes negatively reshaping the brain in neurodegenerative disorders. J Neurochem. 2021 Dec;159(6):958-979. doi: 10.1111/jnc.15525. Epub 2021 Oct 31. PMID: 34657288; PMCID: PMC8688321. 14: Niu M, Song S, Su Z, Wei L, Li L, Pu W, Zhao C, Ding Y, Wang J, Cao W, Gao Q, Wang H. Inhibition of heat shock protein (HSP) 90 reverses signal transducer and activator of transcription (STAT) 3-mediated muscle wasting in cancer cachexia mice. Br J Pharmacol. 2021 Nov;178(22):4485-4500. doi: 10.1111/bph.15625. Epub 2021 Aug 4. PMID: 34265073. 15: Kim JW, Cho YB, Lee S. Correction: Kim et al. Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy. Cells 2021, 10, 670. Cells. 2021 May 14;10(5):1198. doi: 10.3390/cells10051198. Erratum for: Cells. 2021 Mar 17;10(3):670. doi: 10.3390/cells10030670. PMID: 34069315; PMCID: PMC8153583. 16: Sugita M, Wilkes DC, Bareja R, Eng KW, Nataraj S, Jimenez-Flores RA, Yan L, De Leon JP, Croyle JA, Kaner J, Merugu S, Sharma S, MacDonald TY, Noorzad Z, Panchal P, Pancirer D, Cheng S, Xiang JZ, Olson L, Van Besien K, Rickman DS, Mathew S, Tam W, Rubin MA, Beltran H, Sboner A, Hassane DC, Chiosis G, Elemento O, Roboz GJ, Mosquera JM, Guzman ML. Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. NPJ Precis Oncol. 2021 May 26;5(1):44. doi: 10.1038/s41698-021-00183-2. PMID: 34040147; PMCID: PMC8155064. 17: Albakova Z, Mangasarova Y, Sapozhnikov A. Heat Shock Proteins in Lymphoma Immunotherapy. Front Immunol. 2021 Mar 18;12:660085. doi: 10.3389/fimmu.2021.660085. PMID: 33815422; PMCID: PMC8012763. 18: Soudan H, Saeed H, Eldemellawy M, Shalaby M, Hassan M, Elkewedi M, El- Nikhely N. Heat shock protein 90α inhibitor, PU-H71 in combination with DHEA promoting apoptosis in triple-negative breast cancer cell line MDA-MB-231. Acta Biochim Pol. 2020 Dec 15;67(4):561-570. doi: 10.18388/abp.2020_5418. PMID: 33319549. 19: Jhaveri KL, Dos Anjos CH, Taldone T, Wang R, Comen E, Fornier M, Bromberg JF, Ma W, Patil S, Rodina A, Pillarsetty N, Duggan S, Khoshi S, Kadija N, Chiosis G, Dunphy MP, Modi S. Measuring Tumor Epichaperome Expression Using [124I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer. JCO Precis Oncol. 2020 Nov 17;4:PO.20.00273. doi: 10.1200/PO.20.00273. PMID: 33283132; PMCID: PMC7713524. 20: Grbovic-Huezo O, Pitter KL, Lecomte N, Saglimbeni J, Askan G, Holm M, Melchor JP, Chandwani R, Joshi S, Haglund C, Iacobuzio-Donahue CA, Chiosis G, Tammela T, Leach SD. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30670-30678. doi: 10.1073/pnas.1920240117. Epub 2020 Nov 16. PMID: 33199632; PMCID: PMC7720119.

View History

BAY-1251152

BAY-1251152

Featured